| XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer J Kim, E McMillan, HS Kim, N Venkateswaran, G Makkar, ... Nature 538 (7623), 114-117, 2016 | 216 | 2016 |
| Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer HS Kim, S Mendiratta, J Kim, CV Pecot, JE Larsen, I Zubovych, BY Seo, ... Cell 155 (3), 552-566, 2013 | 199 | 2013 |
| BubR1 acetylation at prometaphase is required for modulating APC/C activity and timing of mitosis E Choi, H Choe, J Min, JY Choi, J Kim, H Lee The EMBO journal 28 (14), 2077-2089, 2009 | 146 | 2009 |
| A mechanism for microRNA arm switching regulated by uridylation H Kim, J Kim, S Yu, YY Lee, J Park, RJ Choi, SJ Yoon, SG Kang, VN Kim Molecular cell 78 (6), 1224-1236. e5, 2020 | 81 | 2020 |
| Bias-minimized quantification of microRNA reveals widespread alternative processing and 3′ end modification H Kim, J Kim, K Kim, H Chang, K You, VN Kim Nucleic acids research 47 (5), 2630-2640, 2019 | 80 | 2019 |
| The breast cancer susceptibility gene BRCA2 is required for the maintenance of telomere homeostasis J Min, ES Choi, K Hwang, J Kim, S Sampath, AR Venkitaraman, H Lee Journal of Biological Chemistry 287 (7), 5091-5101, 2012 | 63 | 2012 |
| Computational detection and suppression of sequence-specific off-target phenotypes from whole genome RNAi screens R Zhong, J Kim, HS Kim, M Kim, L Lum, B Levine, G Xiao, MA White, Y Xie Nucleic acids research 42 (13), 8214-8222, 2014 | 28 | 2014 |
| Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers J Kim International Journal of Molecular Sciences 24 (23), 16933, 2023 | 3 | 2023 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING MIR-324 and TUT4/7 EXPRESSION MODULATORS VN KIM, H Kim, KIM Jimi US Patent App. 17/385,277, 2021 | | 2021 |
